Symptoms of lymphomas include peripheral lymphadenopathy, B-symptoms, and other organ-specific symptoms; however, data on initial symptoms incidence in diffuse large B-cell lymphoma (DLBCL) remain limited. We aimed to investigate real-world patterns of initial DLBCL symptoms, correlating them with baseline characteristics and symptom onset-to-diagnosis interval. Patients with DLBCL diagnosed between 2010 and 2021 receiving R-CHOP were screened. 706 individuals with reported initial symptoms were analyzed. 682 (97%) patients had documented symptoms; remaining 24 patients (3%) had incidental findings discovered during examinations for unrelated reasons. Abdominal/gastrointestinal complaints were the most prevalent symptoms (26%), followed by peripheral lymphadenopathy (22%), and B-symptoms (13%). The median symptom-to-diagnosis interval was 10 weeks. Peripheral lymphadenopathy and testicular tumors correlated with low-risk characteristics, with testicular DLBCL featuring a shorter symptom-to-diagnosis interval. Limb pain/swelling and back pain were associated with high-risk characteristics and prolonged symptom-to-diagnosis interval. This analysis enhances our understanding of DLBCL symptomatology, aiding in timely recognition and management.
- Klíčová slova
- Non-Hodgkin lymphoma, diffuse large B-cell lymphoma, extranodal lymphoma, symptoms, time to diagnosis,
- MeSH
- cyklofosfamid terapeutické užití MeSH
- difúzní velkobuněčný B-lymfom * diagnóza farmakoterapie epidemiologie MeSH
- dospělí MeSH
- doxorubicin terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- prednison terapeutické užití MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- rituximab terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- vinkristin terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- cyklofosfamid MeSH
- doxorubicin MeSH
- prednison MeSH
- R-CHOP protocol MeSH Prohlížeč
- rituximab MeSH
- vinkristin MeSH
BACKGROUND: Nanomedicine approaches for cancer therapy face significant challenges, including a poor tumor accumulation, limited therapeutic efficacy, and systemic toxicity. We hypothesized that controlling the clustering of poly(acrylic acid-co-maleic acid) (PAM)-coated superparamagnetic iron oxide nanoparticles (SPIONs) would enhance their magnetic properties for improved targeting, while enabling a pH-responsive drug release in tumor microenvironments. METHODS: PAM-stabilized SPION clusters were synthesized via arrested precipitation, characterized for physicochemical and magnetic properties, and evaluated for doxorubicin loading and pH-dependent release. A dual targeting approach combining antibody conjugation with magnetic guidance was assessed in cellular models, including a novel alternating magnetic field (AMF) pre-treatment protocol. RESULTS: PAM-SPION clusters demonstrated controlled size distributions (60-100 nm), excellent colloidal stability, and enhanced magnetic properties, particularly for larger crystallites (13 nm). The formulations exhibited a pH-responsive drug release (8.5% at pH 7.4 vs. 14.3% at pH 6.5) and a significant enhancement of AMF-triggered release (17.5%). The dual targeting approach achieved an 8-fold increased cellular uptake compared to non-targeted formulations. Most notably, the novel AMF pre-treatment protocol demonstrated an 87% improved therapeutic efficacy compared to conventional post-treatment applications. CONCLUSIONS: The integration of targeting antibodies, magnetic guidance, and a pH-responsive PAM coating creates a versatile theranostic platform with significantly enhanced drug delivery capabilities. The unexpected synergistic effect of the AMF pre-treatment represents a promising new approach for improving the therapeutic efficacy of nanoparticle-based cancer treatments.
- Klíčová slova
- alternating magnetic field, cancer therapy, drug delivery, hyperthermia, magnetic targeting, pH-responsive, superparamagnetic iron oxide nanoparticles, theranostic,
- MeSH
- akrylové pryskyřice * chemie MeSH
- doxorubicin * chemie farmakologie MeSH
- koncentrace vodíkových iontů MeSH
- lékové transportní systémy MeSH
- lidé MeSH
- magnetické nanočástice oxidů železa * chemie MeSH
- magnetické nanočástice * chemie MeSH
- maleáty * chemie MeSH
- nádorové buněčné linie MeSH
- nádory * farmakoterapie MeSH
- nosiče léků chemie MeSH
- uvolňování léčiv MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- akrylové pryskyřice * MeSH
- carbopol 940 MeSH Prohlížeč
- doxorubicin * MeSH
- magnetické nanočástice * MeSH
- maleáty * MeSH
- nosiče léků MeSH
Topoisomerase II alpha and beta (TOP2A and TOP2B) isoenzymes perform essential and non-redundant cellular functions. Anthracyclines induce their potent anti-cancer effects primarily via TOP2A, but at the same time they induce a dose limiting cardiotoxicity through TOP2B. Here we describe the development of the obex class of TOP2 inhibitors that bind to a previously unidentified druggable pocket in the TOP2 ATPase domain to act as allosteric catalytic inhibitors by locking the ATPase domain conformation with the capability of isoform-selective inhibition. Through rational drug design we have developed topobexin, which interacts with residues that differ between TOP2A and TOP2B to provide inhibition that is both selective for TOP2B and superior to dexrazoxane. Topobexin is a potent protectant against chronic anthracycline cardiotoxicity in an animal model. This demonstration of TOP2 isoform-specific inhibition underscores the broader potential to improve drug specificity and minimize adverse effects in various medical treatments.
- MeSH
- antracykliny * škodlivé účinky farmakologie MeSH
- DNA-topoisomerasy typu II * metabolismus chemie MeSH
- inhibitory topoisomerasy II * farmakologie chemie MeSH
- kardiotonika * farmakologie chemie MeSH
- kardiotoxicita * prevence a kontrola MeSH
- lidé MeSH
- myši MeSH
- proteiny vázající poly-ADP-ribosu antagonisté a inhibitory metabolismus chemie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antracykliny * MeSH
- DNA-topoisomerasy typu II * MeSH
- inhibitory topoisomerasy II * MeSH
- kardiotonika * MeSH
- proteiny vázající poly-ADP-ribosu MeSH
- TOP2A protein, human MeSH Prohlížeč
- TOP2B protein, human MeSH Prohlížeč
Multidrug resistance (MDR) represents one of the major concerns in cancer therapy as it may cause reduced efficacy of chemotherapeutic drugs due to the overexpression of ABC transporters, particularly P-glycoprotein (P-gp). This study explores the potential of novel amphiphilic diblock (DB) copolymers composed of poly[N-(2-hydroxypropyl)methacrylamide]-based copolymers (PHPMA) and poly(propylene oxide) (PPO) to overcome MDR mechanisms. The DB copolymers and their doxorubicin (Dox) conjugates significantly increased Dox accumulation in P-gp positive cells, markedly sensitizing them to Dox cytotoxic activity. The underlying mechanisms included depletion of intracellular ATP with subsequent inhibition of P-gp mediated drug efflux, an altered mitochondrial membrane potential, and increased ROS production. Moreover, the DB-Dox conjugates inhibited tumor growth in vivo more effectively compared to the corresponding PHPMA-based drug delivery system. Copolymers with additionally loaded PPO in the micelle core demonstrated superior efficacy in terms of P-gp inhibition, ATP depletion, and chemosensitizing effect in vitro, as well as antitumor activity in vivo. DB copolymers effectively depleted ATP levels both in vitro and in vivo using patient-derived xenograft (PDX) models, underscoring their capacity to enhance the effectiveness of standard chemotherapy and translational potential.
- Klíčová slova
- Diblock copolymers, Drug delivery system, HPMA copolymer, Intracellular ATP depletion, Multidrug resistance, P-glycoprotein inhibition, PPO, Sensitization to chemotherapy,
- MeSH
- adenosintrifosfát metabolismus MeSH
- chemorezistence účinky léků MeSH
- doxorubicin * aplikace a dávkování chemie terapeutické užití MeSH
- lidé MeSH
- methakryláty chemie MeSH
- micely MeSH
- mnohočetná léková rezistence účinky léků MeSH
- myši inbrední BALB C MeSH
- myši nahé MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nádory farmakoterapie metabolismus patologie MeSH
- nosiče léků * chemie MeSH
- P-glykoprotein * metabolismus MeSH
- polymery chemie MeSH
- polypropyleny * chemie MeSH
- propylenglykoly * chemie aplikace a dávkování MeSH
- protinádorová antibiotika * aplikace a dávkování chemie terapeutické užití MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- adenosintrifosfát MeSH
- doxorubicin * MeSH
- methakryláty MeSH
- micely MeSH
- nosiče léků * MeSH
- P-glykoprotein * MeSH
- polymery MeSH
- polypropylene glycol MeSH Prohlížeč
- polypropyleny * MeSH
- propylenglykoly * MeSH
- protinádorová antibiotika * MeSH
Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer in the open-label phase III SOLO3 trial (ClinicalTrials.gov identifier: NCT02282020). We report final overall survival (OS; prespecified secondary end point), post hoc OS analysis by number of previous chemotherapy lines, and exploratory BRCA reversion mutation analysis. Two hundred sixty-six patients were randomly assigned 2:1 to olaparib tablets (300 mg twice daily; n = 178) or physician's choice of single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan; n = 88). OS was similar with olaparib versus chemotherapy (hazard ratio [HR], 1.07 [95% CI, 0.76 to 1.49]; P = .71, median 34.9 and 32.9 months, respectively, full analysis set). OS with olaparib was favorable in patients with two previous chemotherapy lines (HR, 0.83 [olaparib v chemotherapy] [95% CI, 0.51 to 1.38]; median 37.9 v 28.8 months); however, a potential detrimental effect was seen in patients with at least three previous chemotherapy lines (HR, 1.33 [95% CI, 0.84 to 2.18]; median 29.9 v 39.4 months). BRCA reversion mutations might have contributed to this finding. No patient randomly assigned to olaparib with a BRCA reversion mutation detected at baseline (6 of 170 [3.5%]) achieved an objective tumor response.
- MeSH
- deoxycytidin analogy a deriváty aplikace a dávkování MeSH
- doba přežití bez progrese choroby MeSH
- dospělí MeSH
- doxorubicin analogy a deriváty aplikace a dávkování MeSH
- ftalaziny * terapeutické užití škodlivé účinky aplikace a dávkování MeSH
- gemcitabin MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru * farmakoterapie MeSH
- nádory vaječníků * farmakoterapie genetika mortalita patologie MeSH
- paclitaxel aplikace a dávkování MeSH
- PARP inhibitory * terapeutické užití škodlivé účinky MeSH
- piperaziny * terapeutické užití škodlivé účinky aplikace a dávkování MeSH
- polyethylenglykoly aplikace a dávkování MeSH
- protein BRCA1 genetika MeSH
- protein BRCA2 genetika MeSH
- protokoly protinádorové kombinované chemoterapie * terapeutické užití škodlivé účinky MeSH
- senioři MeSH
- topotekan aplikace a dávkování MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- BRCA1 protein, human MeSH Prohlížeč
- BRCA2 protein, human MeSH Prohlížeč
- deoxycytidin MeSH
- doxorubicin MeSH
- ftalaziny * MeSH
- gemcitabin MeSH
- liposomal doxorubicin MeSH Prohlížeč
- olaparib MeSH Prohlížeč
- paclitaxel MeSH
- PARP inhibitory * MeSH
- piperaziny * MeSH
- polyethylenglykoly MeSH
- protein BRCA1 MeSH
- protein BRCA2 MeSH
- topotekan MeSH
PURPOSE: Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell viability and tumor progression. The pivotal, phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 study evaluated efficacy and safety of TTFields therapy with paclitaxel (PTX) vs PTX in patients with platinum-resistant ovarian cancer (PROC). PATIENTS AND METHODS: Adult patients with PROC with ≤ 5 total prior lines of therapy (LOT), including ≤ 2 prior LOT for platinum-resistant disease, and ECOG PS of 0-1 were randomized 1:1 to receive TTFields (200 kHz; ≥ 18 h/day) + PTX (80 mg/m2 weekly) or PTX. Primary endpoint was overall survival (OS). Exploratory post-hoc analyses assessed OS in pegylated liposomal doxorubicin (PLD)-naive patients. RESULTS: Between March 2019 and November 2021, 558 patients (ECOG PS 0, 60.2 %; median [range] age, 62 [22-91] years) were assigned TTFields+PTX (n = 280) or PTX (n = 278). 24.4 % had 4 + prior LOT. Median OS was 12.2 months with TTFields+PTX vs 11.9 months with PTX (HR, 1.01; 95 % CI, 0.83-1.24; p = 0.89). Grade ≥ 3 adverse events (AEs) were similar between treatment groups. Grade 1/2 device-related skin AEs occurred in 83.6 % of patients receiving TTFields therapy. In exploratory post-hoc analysis in PLD-naive patients, median OS was 16 months with TTFields+PTX (n = 113) vs 11.7 months with PTX (n = 88; nominal HR, 0.67; 95 % CI, 0.49-0.94; p = 0.03). CONCLUSIONS: No new safety signals were identified. TTFields+PTX did not significantly improve OS compared with PTX in the intent-to-treat population. An exploratory post-hoc analysis suggests a potentially favorable benefit-risk profile for TTFields therapy in PLD-naive patients.
- Klíčová slova
- Antineoplastic agents, Neoplasm drug resistance, Ovarian epithelial carcinoma, Ovarian neoplasm, Survival analysis,
- MeSH
- chemorezistence * MeSH
- dospělí MeSH
- doxorubicin analogy a deriváty farmakologie terapeutické užití MeSH
- elektrostimulační terapie * škodlivé účinky metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- nádory vaječníků * terapie mortalita patologie farmakoterapie MeSH
- paclitaxel * farmakologie terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- doxorubicin MeSH
- paclitaxel * MeSH
Investigation determines the beneficial effect of bergaptol against gestational diabetes (GD). Gestational diabetes was induced in female rats and treated them with bergaptol 20 and 40 mg/kg for eighteen days. Effect of bergaptol was assessed on blood glucose and insulin level in GD rat. Inflammatory mediators and oxidative stress parameters were also assessed in GD rats. Moreover, mRNA expression of INSR, NF-kappaB, Akt and GSK-3beta were assessed in the GD rats by qRT-PCR method. In silico network pharmacology study was performed, along with gene ontology and egg pathway to assessed the targets of bergaptol, molecular docking study was also performed for the confirmation of possible pathway involved in the management of GD. Blood glucose and insulin level was significantly reduces in the blood bergaptol treated group than GD group of rats. Treatment with bergaptol ameliorates the altered level of mediators of inflammation and oxidative stress parameters in GD rats. There was significant reduction in the mRNA expression of NF-kappaB and GSK-3beta and increase in expression of INSR and Akt in the tissue homogenate of bergaptol treated GD rats. Docking study shows effective binding strength of bergaptol individually with INSR, NF-kappaB, Akt and GSK-3beta-protein targets. In conclusion, data of investigation suggest that bergaptol improves the sensitivity of insulin receptor in GD, as it reduces parameters of oxidative stress and inflammatory mediators by regulating INSR/NF-kappaB/Akt/GSK-3beta pathway. Key words Gestational diabetes, Bergaptol, Insulin resistance, Inflammation, Oxidative stress.
- MeSH
- experimentální diabetes mellitus * farmakoterapie metabolismus chemicky indukované MeSH
- gestační diabetes * farmakoterapie metabolismus chemicky indukované krev MeSH
- inzulinová rezistence * fyziologie MeSH
- krevní glukóza účinky léků metabolismus MeSH
- krysa rodu Rattus MeSH
- mediátory zánětu * antagonisté a inhibitory metabolismus MeSH
- oxidační stres účinky léků MeSH
- potkani Wistar MeSH
- signální transdukce účinky léků MeSH
- simulace molekulového dockingu MeSH
- streptozocin MeSH
- těhotenství MeSH
- zánět metabolismus farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- krevní glukóza MeSH
- mediátory zánětu * MeSH
- streptozocin MeSH
Malignant lymphoma survivors are at increased risk for anthracycline and/or radiotherapy-induced chronic cardiotoxicity. Proper long-term follow-up is essential for malignant lymphoma survivors after-care. This study aimed to assess TTE parameters of potential subclinical cardiotoxicity and to examine their utility in diagnosing chronic cardiotoxicity. Improvement of the diagnostic process may precede the manifestation of cardiac adverse events. Main objective of the study was to improve the identification of cancer survivors in increased risk of treatment cardiotoxicity. To achieve this goal, utility of various echocardiography parameters was examined.In this retrospective study we analysed TTE of 167 subjects with speckle tracking according to the European Society of Echocardiography guidelines during the follow-up period. 88 of them were long-term lymphoma survivors diagnosed with malignant lymphoma between the years 1994-2015. Minimum follow up period was 5 years with the median of 10 years after anti-cancer treatment cessation. TTE were performed between the years 2017-2022 at cardio-oncology outpatient office during regular follow-up period. A total of 79 volunteers with no history of chronic heart failure (CHF) or decline in LVEF, 51 (64.6%) of whom were males, with the median age of 46 (16-58) years were included in the analysis as control group. Control subjects had various indications for TTE (e.g. preoperative examination, benign palpitations, or with well controlled arterial hypertension taking two antihypertensives at most). Ischemic heart disease was ruled out by stress test. None of the control subjects had history of stroke or chronic lower limb ischemia. All control subjects were considered clinically stable with no sign of cardiac impairment caused by primary disease. Both cancer survivors and control group were divided into subgroups based on LVEF: lower normal LVEF (53-61%), and higher normal LVEF (> 61%). Survivors with lower normal LVEF (53-61%) had a statistically significant decline in GLS compared to those with higher normal LVEF (> 61%). This phenomenon was not observed in control group indicating a possible additional diagnostic value of this parameter. Inclusion of GLS assessment in follow-up TTE examination of subjects with lower normal LVEF may improve the sensitivity of detection of chronic cardiotoxicity. Patients with declined GLS and lower normal LVEF are candidates for intensified follow-up to precede manifestation of cardiac adverse events.
- Klíčová slova
- Anthracyclines, Cardiotoxicity, Echocardiography, Global longitudinal strain, Radiotherapy,
- MeSH
- antracykliny škodlivé účinky MeSH
- dospělí MeSH
- echokardiografie metody MeSH
- funkce levé komory srdeční * MeSH
- globální longitudinální strain MeSH
- kardiotoxicita * etiologie diagnóza diagnostické zobrazování MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfom * farmakoterapie komplikace MeSH
- mladiství MeSH
- mladý dospělý MeSH
- následné studie MeSH
- přežívající onkologičtí pacienti * MeSH
- retrospektivní studie MeSH
- tepový objem * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antracykliny MeSH
Acute kidney injury (AKI) due to gentamicin nephrotoxicity is a significant concern in clinical medicine, particularly in patients receiving prolonged or high-dose gentamicin therapy. Gentamicin is an aminoglycoside antibiotic frequently used in the treatment of a range of bacterial infections. However, its use is associated with nephrotoxicity which can manifest as AKI. Due to this, it is crucial to diagnose promptly and manage treatment effectively. Ongoing studies are therefore focusing on non-protein-coding RNAs as potential biomarkers for AKI. Numerous microRNAs (miRNAs) have been implicated in gentamicin-induced nephrotoxicity and AKI. They participate in pathways associated with inflammation, cell death, and oxidative stress and each of these factors play critical roles in the development of gentamicin-induced kidney injury. Research studies have demonstrated changes in the expression levels of these miRNAs in response to gentamicin exposure both in vitro and in in vivo models, as well as in human clinical trials involving patients receiving gentamicin therapy. The dysregulation of these miRNAs correlates with the severity of kidney injury and may serve as sensitive biomarkers for early detection and monitoring of AKI induced by gentamicin.
- Klíčová slova
- acute kidney injury, biomarkers, gentamicin, miRNA, nephrotoxicity,
- MeSH
- akutní poškození ledvin * chemicky indukované diagnóza MeSH
- antibakteriální látky * škodlivé účinky MeSH
- biologické markery metabolismus MeSH
- gentamiciny * škodlivé účinky MeSH
- lidé MeSH
- mikro RNA * metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- antibakteriální látky * MeSH
- biologické markery MeSH
- gentamiciny * MeSH
- mikro RNA * MeSH
Doxorubicin (DOX) is a widely used chemotherapeutic agent known for intercalating into DNA. However, the exact modes of DOX interactions with various DNA structures remain unclear. Using molecular dynamics (MD) simulations, we explored DOX interactions with DNA duplexes (dsDNA), G-quadruplex, and nucleosome. DOX predominantly stacks on terminal bases of dsDNA and occasionally binds into its minor groove. In the G-quadruplex, DOX stacks on planar tetrads but does not spontaneously intercalate into these structures. Potential of mean force calculations indicate that while intercalation is the most energetically favorable interaction mode for DOX in dsDNA, the process requires overcoming a significant energy barrier. In contrast, DOX spontaneously intercalates into bent nucleosomal DNA, due to the increased torsional stress. This preferential intercalation of DOX into regions with higher torsional stress provides new insights into its mechanism of action and underscores the importance of DNA tertiary and quaternary structures in therapies utilizing DNA intercalation.
- Klíčová slova
- DNA, G‐quadruplex, MD simulations, doxorubicin intercalation, intercalation, nucleosome,
- MeSH
- DNA * chemie MeSH
- doxorubicin * chemie MeSH
- G-kvadruplexy MeSH
- interkalátory chemie MeSH
- konformace nukleové kyseliny MeSH
- nukleozomy * chemie MeSH
- protinádorová antibiotika * chemie MeSH
- simulace molekulární dynamiky * MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- DNA * MeSH
- doxorubicin * MeSH
- interkalátory MeSH
- nukleozomy * MeSH
- protinádorová antibiotika * MeSH